Aller au contenu principal
xMedica

NCT07578116ClinicalTrials.gov

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer With Response to Initial Chemotherapy

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with…

Phase 3562 participants recherchés59 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-05-11; recorded start 2027-03-09
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 72 other studies in this databaseCounted from the lead sponsor named in the record (SWOG Cancer Research Network)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 3 conditions.
  • Lead sponsor type recorded as: research network.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourMODERATE

A moderately rigorous design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 562 participants (target), run at 59 sites.

How this score is built
  • Enrolment27/40

    562 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration10/10

    Planned over about 76 months

  • Sponsor scale7/10

    SWOG Cancer Research Network has led 72 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with HER2-positive stage IV breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or to a limited number of sites (oligometastatic). The usual approach for patients with (oligo)metastatic HER2-positive breast cancer is systemic drug treatment, which means medicines that travel through the whole body to treat both the breast and any areas where the cancer has spread. There are a number of approved HER2-targeted systemic therapy regimens available to patients. These typically include immunotherapy and/or chemotherapy. Immunotherapy drugs may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Unlike systemic therapy, locoregional therapies like surgery and radiation are focused treatments at the site of disease, delivered with the intent of sparing healthy tissues. Breast surgeries such as breast conserving therapy or total mastectomy are procedures in which the cancerous breast tissue (and healthy breast tissue in the case of total mastectomy) are surgically removed from the body. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Adding locoregional therapy, as well as metastasis-directed SBRT, to standard systemic therapy may help patients with (oligo)metastatic, HER2-positive stage IV breast cancer live longer overall or before their cancer progresses, and may help more patients achieve no evidence of disease, when compared to standard systemic therapy alone.

PRIMARY OBJECTIVES: I. To compare overall survival (OS) between participants with de novo stage IV oligometastatic HER2+ breast cancer who experience at least a partial response (PR) after initial systemic therapy similar to those used in stage III disease with curative intent, and are randomized to a multimodality approach including definitive locoregional therapy with surgery and radiotherapy and ablative intent stereotactic radiotherapy to detectable metastatic lesions followed by additional HER2-directed systemic therapy, similar to those used for residual disease after neoadjuvant therapy, (Cohort A, Arm 1) versus those who are randomized to physician's choice standard of care HER2-directed systemic therapies without local and metastasis directed ablative therapies (Cohort A, Arm 2). (Randomized Cohort A) II. To evaluate the distribution of progression-free survival (PFS) and overall survival (OS) among participants with de novo stage IV oligometastatic HER2+ breast cancer who do not experience a response after systemic therapy. (Observational Cohort B) SECONDARY OBJECTIVES: I. To compare progression-free survival (PFS) in Cohort A, Arm 1 (randomized to multimodality therapy) versus Cohort A, Arm 2 (randomized to standard of care HER2-directed systemic therapy). (Randomized Cohort) II. To compare PFS in Cohort A, Arm 1 per protocol (received all multimodality therapy as planned) versus Cohort A, Arm 2. (Randomized Cohort) III. To compare OS in Cohort A, Arm 1 per protocol (received all multimodality therapy as planned) versus Cohort A, Arm 2. (Randomized Cohort) IV. To assess duration of standard of care first line systemic therapy received from time of response assessment in Cohort B. (Observational Cohort) BANKING OBJECTIVE: I. To bank specimens for future correlative studies. OUTLINE: STEP 1: Patients receive physician's choice of HER2-targeted systemic therapy according to National Comprehensive Cancer Network (NCCN)/American Society of Clinical Oncology (ASCO) guidelines until completion of at least 12 weeks (4 cycles) or up to 24 weeks (8 cycles) of HER2-targeted therapy prior to Step 2 registration. Patients with brain metastases may also undergo stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) at the discretion of the treating physician. STEP 2: Patients with partial or complete response in the breast following completion of Step 1 are assigned to Cohort A. Patients with clinically stable or progressive disease following completion of Step 1 are assigned to Cohort B. COHORT A: Patients are randomized to 1 of 2 arms. ARM 1: LOCOREGIONAL THERAPY: Patients undergo breast surgery (either breast conserving therapy or total mastectomy) within 4-6 weeks of completion of Step 1 systemic therapy. Within 8 weeks of breast surgery, patients undergo locoregional radiation therapy (RT) to the breast, with or without RT to the breast/chest wall and/or regional lymph nodes, over 5-16 fractions. Patients may undergo RT boost to the lumpectomy bed over 4-5 fractions at the discretion of the treating physician. STEREOTACTIC BODY RADIATION THERAPY (SBRT): Within 4-6 weeks of completion of locoregional therapy, patients undergo SBRT, with or without concurrent adjuvant therapy (pertuzumab and trastuzumab, or trastuzumab emtansine \[T-DM1\], or trastuzumab deruxtecan \[T-DXd\] with or without pertuzumab), to all targetable metastatic lesions every other day for 1, 3, or 5 fractions over a maximum of 3 weeks. POST-LOCOREGIONAL THERAPY AND SBRT: Following recovery from surgery, patients resume systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines for at least 1 year in the absence of disease progression or unacceptable toxicity. Patients who are estrogen receptor positive may also receive endocrine therapy, with or without CDK4/6 inhibitors, at the discretion of the treating physician for at least 5 years, in the absence of disease progression or unacceptable toxicity. ARM 2: Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines for at least 1 year in the absence of disease progression or unacceptable toxicity. Patients may receive locoregional therapy and/or SBRT according to standard of care only if required for palliative purposes. COHORT B: Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines in the absence of disease progression or unacceptable toxicity. All patients also undergo echocardiography (ECHO), magnetic resonance imaging (MRI), mammography, ultrasound, computed tomography (CT), and/or positron emission tomography (PET)/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial. After completion of study treatment, patients registered to Step 2 are followed up for 10 years.

Affections

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic HER2-Positive Breast Carcinoma
  • Oligometastatic Breast Carcinoma

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * REGISTRATION STEP 1 - SCREENING \& INITIAL TREATMENT: * Participants must have histologically confirmed de novo metastatic (i.e. American Joint Committee on Cancer \[AJCC\] stage IV, no prior history of breast cancer) HER2+ breast cancer with 1 to 5 distant metastatic lesions (oligometastatic). Metastatic breast cancer must be histologically confirmed through biopsy of a distant metastatic lesion unless it is not feasible or safe to biopsy a metastatic lesion, then there must be unequivocal evidence of metastasis on imaging and laboratory studies. HER2+ status must be confirmed in the breast tumor and distant metastatic site as defined per NCCN guidelines version 4.2025 * NOTE: If HER2 positivity at metastatic site is equivocal due to limitations in HER2 analysis in bone, or it is not feasible or safe to biopsy the metastatic lesion, then HER2 positivity based on breast tumor only is acceptable. If there is no breast lesion, HER2+ must be confirmed in at least one metastatic site * Participants with brain metastases are eligible if they meet all of the following criteria at baseline: * There are 5 or fewer intracranial lesions * Each intracranial lesions is no larger than 2cm in longest dimension * NOTE: The brain is counted as 1 distant site towards the oligometastatic definition. Brain imaging is not required for participants who have no neurological signs or symptoms suggestive of central nervous system (CNS) involvement; however, assessment of neurological symptoms and brain MRI is strongly encouraged to rule out CNS disease * Participants must have no known leptomeningeal disease * Participants must meet one of the following criteria prior to Step 1 registration: * Treatment naïve and planning to initiate standard of care systemic HER2+ targeted treatment OR * Have already initiated standard of care systemic HER2+ targeted treatment and have completed at least one (≥ 1) but no more than three (≤ 3) cycles prior to enrollment, without progression * NOTE: Standard of care scans for baseline disease assessment must have been performed within 28 days prior to initiation of treatment * Participants must not be receiving or planning to receive any investigational systemic therapy during study before disease progression * Participants must not have received whole brain irradiation * NOTE: Participants with up to five brain metastases may have received SRS/SRT either before or after initiation of systemic therapy. If lesions are small and asymptomatic and the participant is receiving CNS penetration they may be managed with observation * Participants must be ≥ 18 years old at the time of registration * Participants must have Zubrod performance status of 0-2 * Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration * Participants must be able to safely receive the physician's choice of standard of care systemic HER2+ targeted treatment per the current Food and Drug Administration (FDA)-approved package insert(s), treating physician's discretion, and institutional guidelines * Participants must be candidates for definitive surgical and radiotherapeutic management of locoregional disease opinion per the discretion of the treating physician * Participants must be able to receive ablative dose stereotactic body radiation therapy (SBRT) to all metastatic lesions identified at baseline, in the opinion of the treating physician * Participants must be offered the opportunity to participate in specimen banking * NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and CIRB regulations * REGISTRATION STEP 2 - COHORT ASSIGNMENT AND RANDOMIZATION: * COHORT A: Participants must be registered to Step 2 within 14 days of staging scans performed after completing Step 1 systemic therapy * COHORT A: Participants must have standard of care (SOC) staging scans and breast imaging performed following 12-24 weeks (minimum of 4 cycles) of initial systemic therapy and within 14 days prior to Step 2 registration * COHORT A: Participants must have experienced partial or complete response in the breast (in the opinion of the treating physician) following 12-24 weeks of initial systemic therapy based on staging scans performed within 14 days prior to Step 2 registration * Participants with breast lesion(s) at diagnosis must have a clinical response on breast imaging per the treating physician * Metastatic lesions, as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) and bone response criteria, must have at least stable disease * Brain metastases treated with SRS/SRT must have at least stable disease as per Response Assessment in Neuro-Oncology Brain Metastases (RANO BM) and must not require steroid treatment * Participants with no known breast lesions at diagnosis must have at least partial response in the metastatic sites as assessed by RECIST and bone response criteria * NOTE: The same imaging modality must be used as in Step 1 * COHORT A: Participants must be eligible for definitive surgical and radiotherapeutic management of locoregional disease per the discretion of the treating physician * COHORT A: Participants must not have metastatic lesions that are not amenable to ablative dose stereotactic body radiation therapy (SBRT) * Lung lesions that completely resolve after systemic therapy will not be targeted with SBRT, as it is not possible to achieve dose build-up * The development of new sclerotic bone lesions after systemic therapy is not to be interpreted as disease progression, and all such lesions should be targeted with SBRT * COHORT B: Participants must be registered to Step 2 within 14 days of staging scans performed after completing Step 1 systemic therapy * COHORT B: Participants must have standard of care (SOC) staging and breast imaging performed following 12-24 weeks (minimum of 4 cycles) of initial systemic therapy and within 14 days prior to Step 2 registration * COHORT B: Participants must experience clinically stable disease or progression following 12-24 weeks (minimum of 4 cycles) of initial systemic therapy and within 14 days prior to Step 2 registration * Participants must have progression in metastatic lesions as assessed by RECIST and bone response criteria or may have stable disease in metastatic lesions by RECIST and bone response criteria if there is progression or no clinical response in the breast * Participants with known breast lesion must have progression or no clinical response on breast imaging as per the treating physician * NOTE: The same modality must be used as in Step 1

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuNONE (0)
Recrutement562 participants recherchés

Promoteur et collaborateurs

  • SWOG Cancer Research Network Promoteur
  • National Cancer Institute (NCI) Collaborateurs

Groupes et interventions

  • Step 1 (HER2-targeted systemic therapy, STS/SRT)EXPERIMENTAL

    Patients receive physician's choice of HER2-targeted systemic therapy according to NCCN/ASCO guidelines until completion of at least 12 weeks (4 cycles) or up to 24 weeks (8 cycles) of HER2-targeted therapy prior to Step 2 registration. Patients with brain metastases may also undergo SRS/SRT at the discretion of the treating physician. All patients also undergo ECHO, MRI, mammography, ultrasound, CT, and/or PET/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.

  • Step 2 Cohort A, Arm 1 (locoregional, SBRT, systemic therapy)EXPERIMENTAL

    See Detailed Description.

  • Step 2 Cohort A, Arm 2 (systemic therapy)EXPERIMENTAL

    Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines for at least 1 year in the absence of disease progression or unacceptable toxicity. Patients may receive locoregional therapy and/or SBRT according to standard of care only if required for palliative purposes. All patients also undergo ECHO, MRI, mammography, ultrasound, CT, and/or PET/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.

  • Step 2 Cohort B (systemic therapy)EXPERIMENTAL

    Patients continue systemic therapy (T-DXd, or T-DM1, or T-DXd with or without pertuzumab, or taxane with trastuzumab and pertuzumab, or trastuzumab with pertuzumab) according to NCCN/ASCO guidelines in the absence of disease progression or unacceptable toxicity. All patients also undergo ECHO, MRI, mammography, ultrasound, CT, and/or PET/CT throughout the trial. Patients may undergo optional biopsy and/or collection of blood samples throughout the trial.

Interventions

  • Intervention Biopsy Procedure

    Undergo biopsy

  • Intervention Biospecimen Collection

    Undergo collection of blood samples

  • Intervention Breast Conservation Treatment

    Undergo breast conserving therapy

  • Intervention Computed Tomography

    Undergo CT and/or PET/CT

  • Médicament Cyclin-Dependent Kinase 4 Inhibitor

    Given CDK4/6 inhibitor

  • Médicament Cyclin-Dependent Kinase 6 Inhibitor

    Given CDK4/6 inhibitor

  • Intervention Echocardiography Test

    Undergo ECHO

  • Médicament HER2-targeted Therapy

    Receive HER2-targeted systemic therapy

  • Médicament Hormone Therapy

    Given endocrine therapy

  • Intervention Magnetic Resonance Imaging

    Undergo MRI

  • Intervention Mammography

    Undergo mammography

  • Produit biologique Pertuzumab

    Given pertuzumab

  • Intervention Positron Emission Tomography

    Undergo PET/CT

  • Radiothérapie Radiation Boost

    Undergo RT boost

  • Radiothérapie Radiation Therapy

    Undergo RT

  • Radiothérapie Stereotactic Body Radiation Therapy

    Undergo SBRT

  • Radiothérapie Stereotactic Radiosurgery

    Undergo SRS/SRT

  • Médicament Taxane Compound

    Given taxane therapy

  • Intervention Total Mastectomy

    Undergo total mastectomy

  • Produit biologique Trastuzumab

    Given trastuzumab

  • Produit biologique Trastuzumab Deruxtecan

    Given T-DXd

  • Produit biologique Trastuzumab Emtansine

    Given T-DM1

  • Intervention Ultrasound Imaging

    Undergo ultrasound

Critères de jugement

  1. Critère de jugement principal

    Overall survival (OS) (Cohort A)

    The primary analysis to evaluate the primary objective in the randomized cohort will be an intent-to treat (ITT) comparison of Arm 1 versus Arm 2 using a stratified log-rank test including all randomized, eligible participants. The hazard ratio and 95% confidence interval (CI) will be estimated by Cox regression including the stratification factors as variables in the model. Primary analyses will be repeated among individuals with brain metastases to understand whether the effect of the intervention differs in this subgroup.

    Délai From date of Step 2 registration to date of death, assessed up to 10 years

  2. Critère de jugement principal

    Progression-free survival (PFS) (Observational Cohort B)

    In the observational cohort, the primary objective will be evaluated by estimating 3- and 5-year survival and corresponding 95% CIs using the Kaplan-Meier estimator. All analyses in the observational cohort will be descriptive. Primary analyses will be repeated among individuals with brain metastases to understand whether the effect of the intervention differs in this subgroup.

    Délai From date of Step 2 registration to date of first documentation of progression or recurrence or death, assessed at 3 and 5 years

  3. Critère de jugement principal

    Overall survival (Observational Cohort B)

    In the observational cohort, the primary objective will be evaluated by estimating 3- and 5-year survival and corresponding 95% CIs using the Kaplan-Meier estimator. All analyses in the observational cohort will be descriptive. Primary analyses will be repeated among individuals with brain metastases to understand whether the effect of the intervention differs in this subgroup.

    Délai From date of Step 2 registration to date of death, assessed at 3 and 5 years

  4. Critère de jugement secondaire

    Progression free survival (Cohort A)

    The primary analysis will be an ITT comparison of Arm 1 versus Arm 2 using a stratified log-rank test including all randomized, eligible participants. The hazard ratio and 95% CI will be estimated by Cox regression including the stratification factors as variables in the model. In addition to the primary analyses, will estimate PFS at 3 years and 5 years in Arm 1 and Arm 2 and corresponding 95% CIs using the Kaplan-Meier estimator.

    Délai From date of Step 2 registration to date of first documentation of progression or recurrence or death, assessed at 3 and 5 years and then up to 10 years

  5. Critère de jugement secondaire

    Overall survival (Cohort A)

    The primary analysis will be an ITT comparison of Arm 1 versus Arm 2 using a stratified log-rank test including all randomized, eligible participants. The hazard ratio and 95% CI will be estimated by Cox regression including the stratification factors as variables in the model. In addition to the primary analyses, will estimate OS at 3 years and 5 years in Arm 1 and Arm 2 and corresponding 95% CIs using the Kaplan-Meier estimator.

    Délai From date of Step 2 registration to date of death, assessed at 3 and 5 years and then up to 10 years

  6. Critère de jugement secondaire

    Duration of standard of care first line systemic therapy (Cohort B)

    Délai From time of response assessment at end of Step 1 up to 10 years

Dates

Dates
Date de début9 mars 2027 (estimée)
Achèvement principal31 mai 2032 (estimée)
Achèvement31 mai 2033 (estimée)
Première publication11 mai 2026 (réelle)
Dernière mise à jour13 octobre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisoctobre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

59 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
OSF Saint Joseph Medical CenterBloomingtonIllinoisEn recrutement
Illinois CancerCare-BloomingtonBloomingtonIllinoisEn recrutement
Illinois CancerCare-CantonCantonIllinoisEn recrutement
Saint Francis Medical CenterCape GirardeauMissouriEn recrutement
Illinois CancerCare-CarthageCarthageIllinoisEn recrutement
Mercy Cancer Center-West LakesCliveIowaEn recrutement
Baptist Memorial Hospital and Cancer Center-ColliervilleColliervilleTennesseeEn recrutement
Baptist Memorial Hospital and Cancer Center-Golden TriangleColumbusMississippiEn recrutement
Decatur Memorial HospitalDecaturIllinoisEn recrutement
Cancer Care Specialists of Illinois - DecaturDecaturIllinoisEn recrutement
Smilow Cancer Hospital-Derby Care CenterDerbyConnecticutEn recrutement
Mercy Medical Center - Des MoinesDes MoinesIowaEn recrutement
Iowa Methodist Medical CenterDes MoinesIowaEn recrutement
Broadlawns Medical CenterDes MoinesIowaEn recrutement
Illinois CancerCare-EurekaEurekaIllinoisEn recrutement
Smilow Cancer Hospital Care Center-FairfieldFairfieldConnecticutEn recrutement
Illinois CancerCare-GalesburgGalesburgIllinoisEn recrutement
Smilow Cancer Hospital Care Center at GreenwichGreenwichConnecticutEn recrutement
Baptist Cancer Center-GrenadaGrenadaMississippiEn recrutement
Smilow Cancer Hospital Care Center - GuilfordGuilfordConnecticutEn recrutement
Smilow Cancer Hospital-Hamden Care CenterHamdenConnecticutEn recrutement
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboroArkansasEn recrutement
Illinois CancerCare-Kewanee ClinicKewaneeIllinoisEn recrutement
Illinois CancerCare-MacombMacombIllinoisEn recrutement
Bon Secours Memorial Regional Medical CenterMechanicsvilleVirginiaEn recrutement
Baptist Memorial Hospital and Cancer Center-MemphisMemphisTennesseeEn recrutement
Bon Secours Saint Francis Medical CenterMidlothianVirginiaEn recrutement
Baptist Memorial Hospital and Cancer Center-Union CountyNew AlbanyMississippiEn recrutement
Smilow Cancer Center/Yale-New Haven HospitalNew HavenConnecticutEn recrutement
Yale UniversityNew HavenConnecticutEn recrutement
Yale-New Haven Hospital North Haven Medical CenterNorth HavenConnecticutEn recrutement
Cancer Care Center of O'FallonO'FallonIllinoisEn recrutement
HSHS Saint Elizabeth's HospitalO'FallonIllinoisEn recrutement
Orlando Health Cancer InstituteOrlandoFloridaEn recrutement
Illinois CancerCare-Ottawa ClinicOttawaIllinoisEn recrutement
Baptist Memorial Hospital and Cancer Center-OxfordOxfordMississippiEn recrutement
Illinois CancerCare-PekinPekinIllinoisEn recrutement
Illinois CancerCare-PeoriaPeoriaIllinoisEn recrutement
OSF Saint Francis Radiation Oncology at Peoria Cancer CenterPeoriaIllinoisEn recrutement
OSF Saint Francis Medical CenterPeoriaIllinoisEn recrutement
Illinois CancerCare-PeruPeruIllinoisEn recrutement
Thomas Jefferson University HospitalPhiladelphiaPennsylvaniaEn recrutement
Illinois CancerCare-PrincetonPrincetonIllinoisEn recrutement
Bon Secours Cancer Institute at Reynolds CrossingRichmondVirginiaEn recrutement
Bon Secours Saint Mary's HospitalRichmondVirginiaEn recrutement
Southern Illinois University School of MedicineSpringfieldIllinoisEn recrutement
Springfield Memorial HospitalSpringfieldIllinoisEn recrutement
Springfield ClinicSpringfieldIllinoisEn recrutement
Smilow Cancer Hospital Care Center at Long RidgeStamfordConnecticutEn recrutement
Smilow Cancer Hospital-Torrington Care CenterTorringtonConnecticutEn recrutement

9 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 13 octobre 2026

    Statut modifié

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. 13 octobre 2026

    Recrutement ouvert

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  3. 13 octobre 2026

    Site ajouté

    59 sites added (59 total)

    059